62nd ASH Annual Meeting and Exposition: 631. CML: Biology and Pathophysiology, excluding Therapy: Mechanisms of Resistance and Progression in CML

Oral and Poster Abstracts
Oral

Biological, apoptosis, HSCs, CML, Diseases, Therapies, cell regulation, Combinations, enzyme inhibitors, Biological Processes, DNA damage, gene therapy, Technology and Procedures, immunotherapy, Cell Lineage, gene editing, NK cells, Myeloid Malignancies, Clinically relevant, hematopoiesis, flow cytometry, immune mechanism, TKI, stem cells, NGS, metabolomics, RNA sequencing, pathogenesis, senescence, signal transduction

Moderators:

Anna M. Eiring, PhD, Texas Tech University Health Science Center El Paso and Ilaria S Pagani, PhD, South Australian Health and Medical Research Institute

Disclosures:

No relevant conflicts of interest to declare.

1:30 PM

709

Prognostic Relevance of Genetic Abnormalities in Blastic Transformation of Chronic Myeloid Leukemia

Yotaro Ochi, MD^1,2^*, Kenichi Yoshida, MD, PhD¹, Ying-Jung Huang³^*, Ming-Chung Kuo, M.D.^3,4^*, Ko Sasaki⁵, Noriko Hosoya^6,7^*, Nobuhiro Hiramoto, MD⁸^*, Rabindranath Bera³^*, Yasuhito Nannya, MD, PhD¹, Yusuke Shiozawa, MD, PhD¹^*, June Takeda, MD¹^*, Yosaku Watatani, MD¹^*, Hideki Makishima, MD, PhD¹, Yuichi Shiraishi, PhD⁹^*, Kenichi Chiba⁹^*, Hiroko Tanaka¹⁰^*, Masashi Sanada, MD¹¹, Takayuki Ishikawa, MD, PhD⁸, Akifumi Takaori-Kondo, MD, PhD², Satoru Miyano, PhD⁹^*, Kinuko Mitani⁵, Seishi Ogawa, MD, PhD^1,12,13 and Lee-Yung Shih, MD^3,4

¹Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
²Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
³Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital-Linkou, Taoyuan, Taiwan
⁴College of Medicine, Chang Gung University, Taoyuan, Taiwan
⁵Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan
⁶Laboratory of Molecular Radiology, Center for Disease Biology and Integrative Medicine, The University of Tokyo, Tokyo, Japan
⁷Department of Medical Genomics, The University of Tokyo, Tokyo, Japan
⁸Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan
⁹Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
¹⁰Department of Integrated Data Science, M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan
¹¹Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
¹²Department of Medicine, Center for Haematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden
¹³Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan

1:45 PM

710

Microrna-142 Deficiency Promotes Chronic Myeloid Leukemia (CML) Transformation from Chronic Phase (CP) to Blast Crisis (BC)

Bin Amber Zhang, PhD¹, Dandan Zhao, MD²^*, Huafeng Wang, MD³^*, Chen Liang, MD³^*, Le Xuan Truong Nguyen, PhD²^*, Junjing Qiao, MD, PhD⁴^*, Shanshan Suo, MD³^*, Yasmin Elhajmoussa³^*, Lucy Ghoda, PhD⁵^*, David Frankhouser⁶^*, Russell Rockne, PhD⁷, Ling Li, PhD⁸, Ya-Huei Kuo, PhD², Mark Boldin, MD, PhD⁹^* and Guido Marcucci, MD⁸

¹Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope, Monrovia, CA
²Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope, Duarte, CA
³Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematology Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope, Duarte, CA
⁴Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Duarte, CA
⁵Department of Hematologic Malignancies Translational Science, Gehr Family Center for Leukemia Research, Beckman Research Institute, City of Hope, Duarte, CA
⁶City of Hope, Beckman Research Institute, Duarte, CA
⁷Beckman Research Institute, Division of Mathematical Oncology, City of Hope National Medical Center, Duarte, CA
⁸Department of Hematologic Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope, Monrovia, CA
⁹Department of Molecular&Cellular Biology, Beckman Research Institute, City of Hope Medical Center, Duarte, CA

2:00 PM

711

Single-Cell Roadmap of Immune Cell Response in Chronic Myeloid Leukemia

Jani Huuhtanen^1,2,3^*, Jason Theodoropoulos, BSc^1,2,3^*, Rebecca Warfvinge, MSc⁴^*, Andreas Burchert, MD⁵, Tiina Kasanen^1,3^*, Jay Klievink, MSc³^*, Shady Adnan Awad, MD^1,3^*, Olli Dufva, MD^1,3^*, Mette Ilander, PhD¹^*, Taina Jaatinen⁶^*, Ulla Olsson-Strömberg, MD, PhD⁷^*, Henrik Hjorth-Hansen, MD⁸, Göran Karlsson, PhD⁴, Harri Lähdesmäki, PhD²^*, Anna Kreutzman, PhD¹^* and Satu Mustjoki, MD, PhD^1,3

¹Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
²Department of Computer Science, Aalto University School of Science, Helsinki, Finland
³Translational Immunology Research program, University of Helsinki, Helsinki, Finland
⁴Division of Molecular Hematology, Lund University, Lund, Sweden
⁵Dep. of Internal Medicine, Hematologgy, Oncology and Immunology, Philips Univ. Marburg, Marburg, Germany
⁶Finnish Red Cross Blood Service (histocompatibility Testing Laboratory), Helsinki, FIN
⁷Department of Hematology, University Hospital Uppsala, Uppsala, Sweden
⁸Department of Hematology, St Olavs Hospital, Trondheim, Norway

2:15 PM

712

Inhibition of PAK6-Mediated Survival and Cell Cycle Controls Selectively Targets Therapy-Resistant CML Stem/Progenitor Cells

Andrew Wu, BSc¹, Min Chen, PhD²^*, Ryan Yen, BSc¹ and Xiaoyan Jiang, MD, PhD³

¹Terry Fox Laboratory, British Columbia Cancer Research Centre, Vancouver, BC, Canada
²Terry Fox Laboratory, British Columbia Cancer, Vancouver, BC, Canada
³Terry Fox Laboratory, BC Cancer Research Centre, Vancouver, BC, Canada

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

631.O1.6 631. CML: Biology and Pathophysiology, excluding Therapy: Mechanisms of Resistance and Progression in CML